Skip to content
PubMed This is a summary of 13 peer-reviewed journal articles Updated
Oncology

Did H. pylori Cause My Stomach Cancer?

At a Glance

While H. pylori is a major cause of stomach cancer overall, diffuse gastric cancer is frequently driven by genetic mutations like CDH1. Treating H. pylori won't cure your cancer, but testing is important to protect your family's health and safeguard any remaining stomach tissue after surgery.

It is possible that an H. pylori (Helicobacter pylori) infection contributed to your diffuse gastric adenocarcinoma, but it is likely not the only cause. While H. pylori is widely recognized as a major cause of stomach cancer overall, its relationship with the diffuse type is complex. Unlike the more common intestinal-type stomach cancer, which is heavily driven by this bacteria, diffuse gastric cancer can frequently develop in people who have never been infected [1][2].

How H. pylori Contributes to Stomach Cancer

H. pylori is a common type of bacteria that infects the stomach lining. For many people, it causes no symptoms, but in some, it triggers persistent inflammation (gastritis). Over time, this chronic inflammation can damage the cells of your stomach lining [3][4].

The bacteria produce specific proteins (known as virulence factors) that can disrupt normal cell function and alter the immune system [5][6]. This ongoing cycle of damage and abnormal cellular repair creates an environment where cancer is more likely to develop. While this process follows a predictable, step-by-step change in the stomach lining for intestinal-type stomach cancers, research shows H. pylori is also a pro-cancerous factor that can contribute to the development of diffuse gastric cancer [1].

Diffuse Gastric Cancer Without H. pylori

Many patients with diffuse gastric adenocarcinoma test negative for H. pylori and show no signs of past infection [7]. In these cases, the cancer is driven by other factors:

  • Genetics: While most diffuse gastric cancers occur randomly (sporadically), the strongest known hereditary cause is a genetic mutation, most commonly in the CDH1 gene. This condition, called Hereditary Diffuse Gastric Cancer (HDGC), significantly increases the lifetime risk of developing the disease, regardless of whether H. pylori is present [8][9].
  • Other Factors: Lifestyle factors, such as smoking, heavily processed diets, or unknown environmental triggers, may also play a role in causing the cancer to develop [10].

Even if you have a genetic mutation like CDH1, an H. pylori infection could potentially act as an additional trigger that promotes the development or progression of the cancer [11].

Does It Matter Now?

Knowing whether H. pylori played a role in your cancer cannot change your diagnosis, as treating the infection will not cure the cancer. Your doctor can often tell if you have the infection simply by examining the biopsy from your endoscopy, though breath or stool tests are sometimes used. Your care team may still check for it, and for genetic mutations, for several important reasons:

  • Family Health (Infection): Because H. pylori is easily passed between family members living in the same household, if you have it, your immediate family might have it too. Treating the infection in your family members can lower their future risk of developing stomach cancer [12].
  • Family Health (Genetics): If your diffuse cancer is driven by a mutation like CDH1 (or others like CTNNA1 that may be on a genetic testing panel), your blood relatives will need genetic counseling to understand their own risks.
  • Surgical Outcomes: Diffuse gastric cancer often requires the surgical removal of the entire stomach (total gastrectomy) [13]. However, if your specific treatment plan involves only a partial removal of your stomach, clearing an H. pylori infection helps protect the remaining stomach tissue from ongoing inflammation and future risk.

If you are wondering about the exact cause of your diffuse gastric adenocarcinoma, the most critical step is discussing both H. pylori testing and genetic testing with your oncology team.

Common questions in this guide

Did H. pylori cause my diffuse gastric cancer?
H. pylori can contribute to diffuse gastric cancer by causing chronic inflammation and cellular damage over time. However, it is rarely the only cause, and many cases develop in people without the infection due to underlying genetic or environmental factors.
Should my family be tested for H. pylori if I have stomach cancer?
Yes, because H. pylori is easily passed between people living in the same household. If you test positive for the infection, treating your immediate family members can help lower their future risk of developing stomach cancer.
What genetic mutations cause diffuse gastric cancer?
The most common hereditary cause of diffuse gastric cancer is a mutation in the CDH1 gene, which leads to Hereditary Diffuse Gastric Cancer (HDGC). Other mutations, such as CTNNA1, may also be involved and can be identified through genetic testing.
Does treating H. pylori help if I already have stomach cancer?
Treating H. pylori will not cure your cancer. However, if your surgery only removes part of your stomach (partial gastrectomy), clearing the infection is important to protect your remaining stomach tissue from ongoing inflammation and future cancer risks.

Questions to Ask Your Doctor

Curated prompts to bring to your next appointment.

  1. 1.Did my biopsy show any signs of an active or past H. pylori infection?
  2. 2.Based on my age and family history, should I be referred to a genetic counselor to test for mutations like CDH1 or CTNNA1?
  3. 3.If my treatment plan involves removing my entire stomach, does my H. pylori status still matter for my personal care?
  4. 4.If I test positive for H. pylori or a genetic mutation, what specific steps should my immediate family take?

Questions For You

Tap a prompt to share your answer — we'll use it plus this page's context to start a tailored conversation.

References

References (13)
  1. 1

    Host pathogen interactions in Helicobacter pylori related gastric cancer.

    Chmiela M, Karwowska Z, Gonciarz W, et al.

    World journal of gastroenterology 2017; (23(9)):1521-1540 doi:10.3748/wjg.v23.i9.1521.

    PMID: 28321154
  2. 2

    Endoscopic and histological features of Helicobacter pylori-negative differentiated gastric adenocarcinoma arising in the antrum.

    Takita M, Ohata K, Inamoto R, et al.

    JGH open : an open access journal of gastroenterology and hepatology 2021; (5(4)):470-477 doi:10.1002/jgh3.12518.

    PMID: 33860098
  3. 3

    Relationship between Helicobacter pylori infection and colorectal polyp/colorectal cancer.

    Liu Y, Yang DQ, Jiang JN, Jiao Y

    World journal of gastrointestinal surgery 2024; (16(4)):1008-1016 doi:10.4240/wjgs.v16.i4.1008.

    PMID: 38690050
  4. 4

    Histopathological Features of Helicobacter pylori Infection in Gastric Mucosa.

    Wang YK, Li C, Zhou YM, et al.

    Journal of inflammation research 2022; (15()):6231-6243 doi:10.2147/JIR.S383075.

    PMID: 36386590
  5. 5

    Influence of Helicobacter pylori virulence factors CagA and VacA on pathogenesis of gastrointestinal disorders.

    Nejati S, Karkhah A, Darvish H, et al.

    Microbial pathogenesis 2018; (117()):43-48 doi:10.1016/j.micpath.2018.02.016.

    PMID: 29432909
  6. 6

    Autoimmunity and H. pylori infection cooperatively promote epithelial tumorigenic differentiation and systemic immune modulation.

    Vazquez EN, Lozano C, Honan AM, et al.

    bioRxiv : the preprint server for biology 2025; doi:10.1101/2025.11.23.690054.

    PMID: 41394553
  7. 7

    Pathological Diversity of Gastric Cancer from the Viewpoint of Background Condition.

    Abe H, Ushiku T

    Digestion 2022; (103(1)):45-53 doi:10.1159/000519337.

    PMID: 34628409
  8. 8

    Surveillance and Surgical Considerations in Hereditary Diffuse Gastric Cancer.

    Gamble LA, Davis JL

    Gastrointestinal endoscopy clinics of North America 2022; (32(1)):163-175 doi:10.1016/j.giec.2021.08.009.

    PMID: 34798984
  9. 9

    Outcomes after prophylactic gastrectomy for hereditary diffuse gastric cancer.

    van der Kaaij RT, van Kessel JP, van Dieren JM, et al.

    The British journal of surgery 2018; (105(2)):e176-e182 doi:10.1002/bjs.10754.

    PMID: 29341148
  10. 10

    Gastric Microbiota Associated with Gastric Precancerous Lesions in Helicobacter pylori-Negative Patients.

    Kim HN, Kim MJ, Jacobs JP, Yang HJ

    Microorganisms 2025; (13(1)) doi:10.3390/microorganisms13010081.

    PMID: 39858849
  11. 11

    Genomically Silent Refractory Gastric Cancer in a Young Patient Exhibits Overexpression of CXCL5.

    Hernandez J, Turner MA, Bali P, et al.

    Current oncology (Toronto, Ont.) 2022; (29(7)):4725-4733 doi:10.3390/curroncol29070375.

    PMID: 35877235
  12. 12

    Mass Eradication of Helicobacter pylorito Prevent Gastric Cancer: Theoretical and Practical Considerations.

    Lee YC, Chiang TH, Liou JM, et al.

    Gut and liver 2016; (10(1)):12-26 doi:10.5009/gnl15091.

    PMID: 26696028
  13. 13

    Hereditary Diffuse Gastric Cancer Syndrome and the Role of CDH1: A Review.

    Gamble LA, Heller T, Davis JL

    JAMA surgery 2021; (156(4)):387-392 doi:10.1001/jamasurg.2020.6155.

    PMID: 33404644

This page is for informational purposes only and does not replace professional medical advice. Always consult your oncology team or a genetic counselor regarding the specific causes and hereditary risks associated with your cancer.

Get notified when new evidence is published on diffuse gastric adenocarcinoma.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.